Eric
Mallack
,
MD, MBE
1741 Ashland Avenue, Room 849
Baltimore, MD 21205
United States
About
Dr. Eric Mallack is the director of clinical research at the Moser Center for Leukodystrophies and an assistant professor of Neurology at The Johns Hopkins School of Medicine. He oversees the clinical, neuroimaging and clinical trial research in the Moser Center and Clinical Trials Unit at the Institute. Clinically, he sees patients in the Newborn Screening Follow-up Clinic, Multidisciplinary Leukodystrophy Clinic and Neurogenetics Clinic.
Education
Dr. Mallack received his undergraduate degree in Philosophy and Biomathematics, with a minor in Biochemistry, from The University of Scranton where he graduated Magna Cum Laude from the Special Jesuit Liberal Arts Honors Program. He simultaneously earned his Medical Doctorate from the Temple University School of Medicine and a Master of Bioethics from the University of Pennsylvania School of Medicine. Dr. Mallack trained in Pediatric Neurology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Following residency, he completed an NIH-funded K12 post-doctoral training program at the Center for Rare Neurological Diseases at Massachusetts General Hospital and earned a Master of Clinical and Translational Science from the Weill Cornell Graduate School of Medical Sciences. He joined the faculty at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center where he founded the tristate area’s first certified Leukodystrophy Center of Excellence and developed a clinical research program in the leukodystrophies funded by an NIH K23 award. Dr. Mallack joined The Moser Center for Leukodystrophies at Kennedy Krieger as the director of clinical research in the fall of 2023.
Research
Dr. Mallack’s research focuses on understanding brain development in the diseased state and enhancing the prediction of disease-onset and progression in cerebral adrenoleukodystrophy (ALD). He has mathematically modeled the early evolution of cerebral ALD on MRI, quantified the natural history of multiple ALD disease phenotypes and developed data-driven clinical and imaging guidelines for boys affected by ALD. This work has been supported by an NIH/NINDS K12 career development award, NIH/NCATS U54 subaward and currently an NIH/NINDS K23 development award.
In addition to providing clinical care for patients of all ages across all leukodystrophies, He serves (or has served) as an investigator for multiple international clinical trials in gene and novel small molecule therapy for neurodegenerative diseases (NCT04771416, NCT04998396, NCT03612869, NCT04528706, NCT05008874, NCT05819866). The regression models developed in his previous work are currently being utilized as primary and secondary quantitative MRI endpoints in an ongoing clinical trial in boys with cerebral ALD (NCT04528706).